BAVARIAN NORDIC A/S (BV3.DE) Stock Fundamental Analysis

FRA:BV3 • DK0015998017

25.69 EUR
-0.03 (-0.12%)
Last: Feb 13, 2026, 07:00 PM
Fundamental Rating

6

Taking everything into account, BV3 scores 6 out of 10 in our fundamental rating. BV3 was compared to 78 industry peers in the Biotechnology industry. BV3 has an excellent financial health rating, but there are some minor concerns on its profitability. BV3 is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, BV3 could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year BV3 was profitable.
  • In the past year BV3 had a positive cash flow from operations.
  • In multiple years BV3 reported negative net income over the last 5 years.
  • BV3 had a positive operating cash flow in 4 of the past 5 years.
BV3.DE Yearly Net Income VS EBIT VS OCF VS FCFBV3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B -2B

1.2 Ratios

  • BV3 has a Return On Assets of 16.13%. This is amongst the best in the industry. BV3 outperforms 91.03% of its industry peers.
  • BV3 has a Return On Equity of 18.58%. This is amongst the best in the industry. BV3 outperforms 85.90% of its industry peers.
  • BV3 has a better Return On Invested Capital (13.14%) than 89.74% of its industry peers.
Industry RankSector Rank
ROA 16.13%
ROE 18.58%
ROIC 13.14%
ROA(3y)4.78%
ROA(5y)2.73%
ROE(3y)6.02%
ROE(5y)3.49%
ROIC(3y)N/A
ROIC(5y)N/A
BV3.DE Yearly ROA, ROE, ROICBV3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

  • With an excellent Profit Margin value of 35.50%, BV3 belongs to the best of the industry, outperforming 91.03% of the companies in the same industry.
  • The Operating Margin of BV3 (36.21%) is better than 92.31% of its industry peers.
  • With a Gross Margin value of 54.33%, BV3 perfoms like the industry average, outperforming 51.28% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BV3 has remained more or less at the same level.
Industry RankSector Rank
OM 36.21%
PM (TTM) 35.5%
GM 54.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.91%
GM growth 5Y1.2%
BV3.DE Yearly Profit, Operating, Gross MarginsBV3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

8

2. Health

2.1 Basic Checks

  • BV3 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, BV3 has more shares outstanding
  • BV3 has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BV3 has been reduced compared to a year ago.
BV3.DE Yearly Shares OutstandingBV3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BV3.DE Yearly Total Debt VS Total AssetsBV3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

2.2 Solvency

  • BV3 has an Altman-Z score of 7.10. This indicates that BV3 is financially healthy and has little risk of bankruptcy at the moment.
  • BV3 has a better Altman-Z score (7.10) than 83.33% of its industry peers.
  • The Debt to FCF ratio of BV3 is 0.10, which is an excellent value as it means it would take BV3, only 0.10 years of fcf income to pay off all of its debts.
  • BV3 has a better Debt to FCF ratio (0.10) than 96.15% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that BV3 is not too dependend on debt financing.
  • BV3 has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. BV3 outperforms 83.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.1
Altman-Z 7.1
ROIC/WACC1.66
WACC7.93%
BV3.DE Yearly LT Debt VS Equity VS FCFBV3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

2.3 Liquidity

  • A Current Ratio of 3.84 indicates that BV3 has no problem at all paying its short term obligations.
  • BV3 has a Current ratio of 3.84. This is in the better half of the industry: BV3 outperforms 73.08% of its industry peers.
  • A Quick Ratio of 2.43 indicates that BV3 has no problem at all paying its short term obligations.
  • The Quick ratio of BV3 (2.43) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.84
Quick Ratio 2.43
BV3.DE Yearly Current Assets VS Current LiabilitesBV3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

5

3. Growth

3.1 Past

  • BV3 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.44%, which is quite impressive.
  • BV3 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.47%.
  • Measured over the past years, BV3 shows a very strong growth in Revenue. The Revenue has been growing by 53.88% on average per year.
EPS 1Y (TTM)39.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%414.42%
Revenue 1Y (TTM)13.47%
Revenue growth 3Y44.42%
Revenue growth 5Y53.88%
Sales Q2Q%32.58%

3.2 Future

  • Based on estimates for the next years, BV3 will show a small growth in Earnings Per Share. The EPS will grow by 5.33% on average per year.
  • The Revenue is expected to grow by 2.85% on average over the next years.
EPS Next Y54.87%
EPS Next 2Y-4.62%
EPS Next 3Y1.7%
EPS Next 5Y5.33%
Revenue Next Year9.45%
Revenue Next 2Y-0.91%
Revenue Next 3Y-0.48%
Revenue Next 5Y2.85%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BV3.DE Yearly Revenue VS EstimatesBV3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
BV3.DE Yearly EPS VS EstimatesBV3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10 15

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 11.32, the valuation of BV3 can be described as reasonable.
  • Compared to the rest of the industry, the Price/Earnings ratio of BV3 indicates a rather cheap valuation: BV3 is cheaper than 96.15% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.68. BV3 is valued rather cheaply when compared to this.
  • BV3 is valuated rather expensively with a Price/Forward Earnings ratio of 20.15.
  • 85.90% of the companies in the same industry are more expensive than BV3, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. BV3 is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 11.32
Fwd PE 20.15
BV3.DE Price Earnings VS Forward Price EarningsBV3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BV3 is valued cheaper than 94.87% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BV3 is valued cheaply inside the industry as 96.15% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.85
EV/EBITDA 3.59
BV3.DE Per share dataBV3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BV3 has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.21
PEG (5Y)N/A
EPS Next 2Y-4.62%
EPS Next 3Y1.7%

0

5. Dividend

5.1 Amount

  • BV3 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

BAVARIAN NORDIC A/S

FRA:BV3 (2/13/2026, 7:00:00 PM)

25.69

-0.03 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-12
Inst Owners28.69%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap2.04B
Revenue(TTM)6.89B
Net Income(TTM)2.44B
Analysts86
Price Target34.14 (32.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.03%
PT rev (3m)-29.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-32.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.52%
Valuation
Industry RankSector Rank
PE 11.32
Fwd PE 20.15
P/S 2.21
P/FCF 11.85
P/OCF 4.86
P/B 1.16
P/tB 2.13
EV/EBITDA 3.59
EPS(TTM)2.27
EY8.84%
EPS(NY)1.28
Fwd EY4.96%
FCF(TTM)2.17
FCFY8.44%
OCF(TTM)5.29
OCFY20.6%
SpS11.63
BVpS22.23
TBVpS12.06
PEG (NY)0.21
PEG (5Y)N/A
Graham Number33.69
Profitability
Industry RankSector Rank
ROA 16.13%
ROE 18.58%
ROCE 18.66%
ROIC 13.14%
ROICexc 16.9%
ROICexgc 40.21%
OM 36.21%
PM (TTM) 35.5%
GM 54.33%
FCFM 18.64%
ROA(3y)4.78%
ROA(5y)2.73%
ROE(3y)6.02%
ROE(5y)3.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.91%
GM growth 5Y1.2%
F-Score8
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.1
Debt/EBITDA 0.03
Cap/Depr 262.4%
Cap/Sales 26.84%
Interest Coverage 81.71
Cash Conversion 97.94%
Profit Quality 52.5%
Current Ratio 3.84
Quick Ratio 2.43
Altman-Z 7.1
F-Score8
WACC7.93%
ROIC/WACC1.66
Cap/Depr(3y)229.46%
Cap/Depr(5y)231.44%
Cap/Sales(3y)29.07%
Cap/Sales(5y)36.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%414.42%
EPS Next Y54.87%
EPS Next 2Y-4.62%
EPS Next 3Y1.7%
EPS Next 5Y5.33%
Revenue 1Y (TTM)13.47%
Revenue growth 3Y44.42%
Revenue growth 5Y53.88%
Sales Q2Q%32.58%
Revenue Next Year9.45%
Revenue Next 2Y-0.91%
Revenue Next 3Y-0.48%
Revenue Next 5Y2.85%
EBIT growth 1Y125.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year111.77%
EBIT Next 3Y18.67%
EBIT Next 5Y18.75%
FCF growth 1Y262.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y316.96%
OCF growth 3YN/A
OCF growth 5YN/A

BAVARIAN NORDIC A/S / BV3.DE FAQ

Can you provide the ChartMill fundamental rating for BAVARIAN NORDIC A/S?

ChartMill assigns a fundamental rating of 6 / 10 to BV3.DE.


What is the valuation status of BAVARIAN NORDIC A/S (BV3.DE) stock?

ChartMill assigns a valuation rating of 8 / 10 to BAVARIAN NORDIC A/S (BV3.DE). This can be considered as Undervalued.


How profitable is BAVARIAN NORDIC A/S (BV3.DE) stock?

BAVARIAN NORDIC A/S (BV3.DE) has a profitability rating of 6 / 10.


What are the PE and PB ratios of BAVARIAN NORDIC A/S (BV3.DE) stock?

The Price/Earnings (PE) ratio for BAVARIAN NORDIC A/S (BV3.DE) is 11.32 and the Price/Book (PB) ratio is 1.16.


What is the financial health of BAVARIAN NORDIC A/S (BV3.DE) stock?

The financial health rating of BAVARIAN NORDIC A/S (BV3.DE) is 8 / 10.